Glaukos Corporation filings document the regulatory record for an ophthalmic pharmaceutical and medical technology company with common stock listed on the New York Stock Exchange under GKOS. Recent Form 8-K reports furnish quarterly and annual financial results, preliminary net sales information, supplemental business summaries, and Regulation FD investor presentations.
The company’s proxy materials provide governance and executive-compensation disclosures, including equity-award and pay-versus-performance information. These filings also identify Glaukos as a Delaware corporation and frame disclosure around its glaucoma, corneal-disorder, and retinal-disease therapies, commercial products, risk disclosures, and public-company reporting obligations.
GLAUKOS Corp (GKOS) Chairman & CEO Thomas William Burns exercised options covering 180,000 common shares on November 18, 2026, at a $45.71 exercise price; the reported option balance afterward was zero. He also sold 180,000 shares that day in multiple trades, with reported transaction-level weighted-average prices ranging from $232.61 to $245.90 per share.
The exercises and sales were made under a Rule 10b5-1 trading plan adopted August 20, 2026, covering options expiring March 15, 2027. The report lists indirect holdings of 1,141,593 shares through the Burns Family Trust, 238,107 through the Burns Annuity Trust, 120,000 through the Burns Charitable Remainder Trust, and 100,000 shares each through the Thomas W. Burns and Janet M. Burns Irrevocable Trusts.
Glaukos Corp. SVP and Chief Financial Officer Alex R. Thurman exercised options for 15,000 common shares at a $45.71 exercise price on November 18, 2026, then sold 15,000 shares at reported weighted-average prices from $232.65 to $246.12 per share in 13 transactions. The option exercise and sales were made under a Rule 10b5-1 trading plan adopted August 18, 2026; the options expire March 15, 2027. The reported option position following the exercise was zero.
Glaukos withheld 3,907 shares from its Chairman & CEO, Thomas William Burns, on April 9, 2024, at $87.61 per share for tax obligations when previously granted restricted stock units vested and were delivered. The Form 4 reports 65,060 securities beneficially owned as of filing, including 48,673 unvested and undelivered restricted stock units.
Glaukos Corp. (GKOS) President & COO Joseph E. Gilliam exercised options covering 861 shares on November 16, 2026, at exercise prices of $48.46, $55.18 and $69.30 per share, and sold 861 common shares at $250 per share. The option exercises and sale were made under a Rule 10b5-1 trading plan adopted August 13, 2026.
GLAUKOS Corp (GKOS) officer and director Thomas William Burns gave notice of a proposed sale of 180,000 common shares, with an aggregate market value of $44,220,600 and an approximate sale date of November 18, 2026. The notice identifies the shares as acquired from the issuer through a stock option exercise on November 18, 2026, with cash payment. It lists a Rule 10b5-1 plan adoption date of August 20, 2026.
GLAUKOS Corp (GKOS) officer Alex R. Thurman filed notice of a proposed sale of 15,000 common shares, with an approximate sale date of November 18, 2026 and an aggregate market value of $3,685,050. The notice lists August 18, 2026 as the Rule 10b5-1 plan adoption or instruction date. It identifies the shares as acquired from the issuer through a stock option exercise on November 18, 2026.
Glaukos Corp (GKOS) President & COO Joseph E. Gilliam exercised options for 44,917 common shares on November 12, 2026. The five reported option lots were 2,475 shares at $69.30, 7,500 shares in each of two lots at $48.46, and 11,250 and 16,192 shares at $55.18 per share.
Gilliam also sold 44,917 shares in six transactions that day; reported weighted-average sale prices ranged from $243.41 to $248.42 per share. The option exercises and sales were effected pursuant to a Rule 10b5-1 trading plan.
GLAUKOS Corp (GKOS) President & COO Joseph E. Gilliam had 986 common shares withheld by the issuer on April 9, 2024, for tax withholding obligations upon vesting and delivery of shares underlying restricted stock units granted March 18, 2021. The reported price was $87.61 per share. Beneficial ownership reported as of the Form 4 filing date was 71,602 shares, including 40,039 restricted stock units not yet vested or delivered.
GLAUKOS Corp officer Joseph Gilliam filed notice of a proposed sale of 861 common shares, with an approximate market value of $215,250.00 and an approximate sale date of November 16, 2026. The notice lists a cash-paid stock option exercise of 861 shares dated November 16, 2026. It also reports that Gilliam sold 44,917 shares for gross proceeds of $11,063,731.77 during the preceding three months.
Glaukos Corp (GKOS) is the issuer covered by Janus Henderson Group Ltd.’s Amendment No. 2, which reports beneficial ownership of 4,629,689 common shares, or 7.9%, as of September 30, 2026. Janus Henderson reported shared voting and dispositive power over all 4,629,689 shares, with no sole voting or dispositive power. The Managed Portfolios hold the rights to dividends and sale proceeds; Janus Henderson disclaims ownership associated with those rights, and none of the Managed Portfolios owns more than 5% of Glaukos common stock.